Viridian debuts on market with FDA greenlight for thyroid eye disease drug
BioSpace covers Viridian Therapeutics' FDA approval of its thyroid eye disease treatment and the company's corresponding market debut.
Viridian Therapeutics
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases and rare conditions, with a focus on FcRn inhibitors and thyroid eye disease.
Company Info
Sector:Antibodies
Headquarters:Waltham, Massachusetts, United States
Founded:2021
Website:www.viridiantherapeutics.com/
Upcoming Milestones & Key Dates
2026-08
Launch
Veligrotug U.S. commercial launch
2026-Q3
Clinical readout
VRDN-003 Phase 3 topline data
Clinical Development Pipeline
Veligrotug (VRDN-001)
Target: IGF-1RVRDN-003
Target: IGF-1RVRDN-008
Target: FcRnRecent News
Viridian set for 1-on-1 vs. Amgen after FDA approval of Lumvoa
Viridian Therapeutics received FDA approval for Lumvoa (veligrotug) to treat thyroid eye disease, positioning the biotech as a direct competitor to Amgen's Tepezza blockbuster.
Viridian may have edge over Amgen in eye drug showdown, analysts argue
Viridian may have edge over Amgen in eye drug showdown, analysts argue (BioPharma Dive.)
Leadership Team
Stephen Mahoney
President and CEO
Jennifer C. Kherani
Chief Medical Officer
Thomas M. Ciulla
Chief Development Officer
Careers & Job Openings